Quantum Genomics


Market Cap€92m

Last Close €2.65


More Quantum Genomics content >

Investment summary

Quantum Genomics has reported the results of the Phase IIb QUORUM study at the European Society of Cardiology. Unfortunately, the primary endpoint of change from baseline in the left ventricular ejection fraction (LVEF) after a 12-week treatment was missed, with essentially no difference between the firibastat 500mg BID arm and the ramipril 5mg BID arm (there was a slight trend in favour of ramipril with a p-value of 0.789). The company noted a trend in firibastat’s favour in patients with an LVEF of less than 50%, but this was also not significant. The company has stated it is moving forward into Phase III in severe patients.

View more
Register to receive research on Quantum Genomics as it is published
Share price graph
Price performance
Actual 38.8 42.4 (44.3)
Relative* 28.5 37.4 (41.3)
52-week high/low €5.9/€1.6
*% relative to local index
Key management
Jean-Philippe Milon CEO
Benoît Gueugnon CFO
Lionel Ségard Founder & Chairman